2006•European Heart JournalRequires access

Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and left ventricular hypertrophy on ECG. : The LIFE study

MH Olsen, Kristian Wachtell, Björn Dahlöf, Lars Hjalmar Lindholm

Open publisher page 1 citations

Abstract

Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and left ventricular hypertrophy on ECG. : The LIFE study

About this research paper

What this paper is about

Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and left ventricular hypertrophy on ECG. : The LIFE study

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and left ventricular hypertrophy on ECG. : The LIFE study

Key concepts: Medicine, Atenolol, Left ventricular hypertrophy, Losartan, Cardiology, Internal medicine, Muscle hypertrophy, Cardiovascular event

Related papers

Back to paper searchBrowse research topicsOriginal source
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and left ventricular hypertrophy on ECG. : The LIFE study — Research Paper | ScholarLens